2-fluoro-5-hydroxy-4-methoxybenzaldehyde | 79418-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-fluoro-5-hydroxy-4-methoxybenzaldehyde
• CAS: 79418-76-1
• 化学式: C₈H₇FO₃
• 分子量: 170.14
• InChiKey: ZWCQCWGXEZSYBY-UHFFFAOYSA-N

物化性质

• 沸点：
  285.1±35.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-fluoro-5-hydroxy-4-methoxybenzaldehyde 在 氯化亚砜 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of L-791,943: A potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor

  摘要：

  Structure-activity relationship studies directed toward improving the potency and metabolic stability of CDP-840 (3) resulted in the discovery of L-791,943 (1 In) as a potent (HWB TNF-alpha = 0.67 muM) and orally active phosphodiesterase type 4 (PDE4) inhibitor. This compound, which bears a stable bis-difluoromethoxy catechol and a pendant hexafluorocarbinol, exhibited a long half-life in rat and in squirrel monkey. It is well tolerated in ferret with an emetic threshold greater than 30 mg/kg (po) and was found to be active in the ovalbumin-induced bronchoconstriction model in guinea pig and in the ascaris-induced bronchoconstriction models in sheep and squirrel monkey. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00190-7
• 作为产物：
  描述：

  6-氟藜芦醛 在 硫酸 作用下， 以85.5 %的产率得到2-fluoro-5-hydroxy-4-methoxybenzaldehyde
  参考文献：
  名称：

  [EN] ARYL AROMATIC HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] DÉRIVÉ D'ARYLE HÉTÉROCYCLIQUE AROMATIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 一种芳基并芳杂环衍生物及其制备方法和用途

  摘要：

  本发明公开了一种芳基并芳杂环衍生物及其制备和用途，结构如式I所示，式中，各取代基的定义如说明书和权利要求书中所述。本发明的化合物，能够用作STING激动剂，用于包括肿瘤、感染性疾病的治疗，或作为免疫组合物或疫苗佐剂。

  公开号：

  WO2022002077A1

文献信息

• [EN] PENICILLIN-BINDING PROTEIN INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE DE LIAISON À LA PÉNICILLINE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2019226931A1

  公开（公告）日：2019-11-28

  Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了某些含硼化合物、组合物、制剂及其作为细菌青霉素结合蛋白的跨肽酶功能调节剂和抗菌剂的用途。在某些实施例中，本文描述的化合物抑制青霉素结合蛋白。在某些实施例中，本文描述的化合物在治疗细菌感染方面是有用的。
• Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
  申请人：Galantos Pharma GmbH

  公开号：EP1777222A1

  公开（公告）日：2007-04-25

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline of neuronal cholinergic receptors and/or acting as chvlinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. galanthamine, narwedine and lyeoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as "prodrugs", in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the psychiatric diseases vascular dementia, schizophrenia and epilepsy.

  本发明涉及化合物，除了增强神经胆碱能受体对乙酰胆碱和胆碱的敏感性，或者作为胆碱酯酶抑制剂和/或神经保护剂之外，与其原始化合物相比具有增强的血脑屏障渗透性。这些化合物来源于属于石蒜科生物碱类的天然化合物，例如迎春碱、纳尔韦丁和莱奥拉明，或者来源于这些化合物的代谢物（无论是从化学结构上还是直接通过化学合成）。本发明的化合物可以直接与其靶分子相互作用，或者它们可以作为“前药”，意味着在到达体内的靶区域后，它们通过水解或酶攻击转化为原始的母体化合物，并且与其靶分子相互作用，或者两者兼而有之。本发明的化合物可用作治疗与胆碱缺乏相关的人类脑疾病的药物，包括神经退行性疾病阿尔茨海默病和帕金森病，以及精神疾病血管性痴呆、精神分裂症和癫痫。
• Synthesis and Radical Scavenging Activities of Resveratrol Analogs
  作者：René Csuk、Sabrina Albert、Bianka Siewert

  DOI：10.1002/ardp.201300081

  日期：2013.7

  polyhydroxylated (E)‐stilbenes were synthesized by Mizoroki–Heck reactions and tested for their ability to act as radical scavenger. One of the 56 stilbenes included in this study and investigated in DPPH assays gave an SC50 value of 11.0 μM, hence exhibiting an about 9.3 times higher activity than resveratrol. As shown in a photometric SRB assay using mouse NiH 3T3 fibroblasts, this compound is not cytotoxic up

  通过 Mizoroki-Heck 反应合成了高度取代的多羟基化 (E)-二苯乙烯，并测试了它们作为自由基清除剂的能力。本研究中包括并在 DPPH 测定中研究的 56 种芪中之一的 SC50 值为 11.0 μM，因此其活性比白藜芦醇高约 9.3 倍。如使用小鼠 NiH 3T3 成纤维细胞的光度 SRB 测定所示，该化合物在浓度小于 30 μM 时没有细胞毒性。
• Compounds as PDE IV and TNF inhibitors
  申请人：Aventis Pharma Limited

  公开号：US06472412B1

  公开（公告）日：2002-10-29

  This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

  该发明涉及一种用于抑制肿瘤坏死因子（TNF）的产生或生理效应的化合物，或其N-氧化物或药用可接受的盐，该化合物适用于治疗患有与生理上有害的肿瘤坏死因子（TNF）过剩相关的疾病状态的患者。本发明范围内的化合物还抑制环状AMP磷酸二酯酶，并且适用于治疗与通过抑制环状AMP磷酸二酯酶调节的病理条件相关的疾病状态，这些疾病状态包括炎症和自身免疫性疾病，特别是第四型环状AMP磷酸二酯酶。因此，本发明涉及它们在药理上用于抑制TNF和/或环状AMP磷酸二酯酶的用途，包括含有这些化合物的药理组合物和其制备方法。
• Resveratrol Derived Butyrylcholinesterase Inhibitors
  作者：René Csuk、Sabrina Albert、Ralph Kluge、Dieter Ströhl

  DOI：10.1002/ardp.201300051

  日期：2013.7

  (E)‐stilbenes were synthesized by Mizoroki–Heck reactions and tested for their ability to inhibit the enzymes acetyl‐ and butyrylcholinesterase. Several of them are good inhibitors of butyrylcholinesterase; one of them carrying an extra fluorine substituent is a 94‐fold stronger inhibitor of butyrylcholinesterase than of acetylcholinesterase.

  通过 Mizoroki-Heck 反应合成了新型多羟基化 (E)-二苯乙烯，并测试了它们抑制乙酰胆碱酯酶和丁酰胆碱酯酶的能力。其中一些是丁酰胆碱酯酶的良好抑制剂；其中一种带有额外氟取代基的丁酰胆碱酯酶抑制剂是乙酰胆碱酯酶抑制剂的 94 倍。